EQ-001 Market Summary

Key Factors Driving EQ-001 Growth

1. First-in-class CD6-ALCAM pathway modulation provides a differentiated mechanism

EQ-001 (Itolizumab) is a first-in-class anti-CD6 monoclonal antibody that selectively inhibits the CD6-ALCAM signaling pathway, reducing pathogenic T-effector cell activation while preserving regulatory T cells. This differentiated mechanism may offer advantages over broader immunosuppressive therapies by maintaining immune homeostasis while controlling inflammation. Because the CD6 pathway is implicated in multiple immune-mediated diseases, EQ-001 has potential applicability across several autoimmune and inflammatory indications, providing significant lifecycle expansion opportunities if approved.

2. Positive durability signals in Phase III acute GvHD support continued development

In March 2025, Equillium reported topline results from the Phase III EQUATOR trial in acute graft-versus-host disease (aGvHD). Although the study did not achieve its primary endpoint of complete response at Day 29 or the key secondary endpoint of overall response rate, EQ-001 demonstrated clinically meaningful improvements in durable complete response through Day 99, statistically significant improvements in duration of complete response and failure-free survival, and favorable trends in overall survival. The drug also maintained a safety profile consistent with previous studies. These longer-term efficacy signals may support future regulatory discussions or partnership opportunities despite the initial setback.

3. Broad therapeutic potential across multiple immune-mediated diseases

The CD6 pathway is involved in numerous T-cell-mediated disorders, making EQ-001 a potential platform therapy beyond aGvHD. Historically, Equillium evaluated or planned development in chronic graft-versus-host disease, lupus nephritis, asthma, alopecia areata, and other autoimmune conditions. Although development priorities have evolved, the underlying biology continues to support expansion into multiple high-value indications, increasing the long-term commercial opportunity if future clinical success is achieved.

4. Orphan Drug Designation provides important regulatory and commercial incentives

The US FDA granted Orphan Drug Designation to EQ-001 for both the prevention and treatment of acute graft-versus-host disease. Orphan designation offers benefits including regulatory assistance, potential market exclusivity upon approval, fee reductions, and development incentives that may accelerate commercialization while improving the product's economic attractiveness in a rare disease setting.

5. Established manufacturing capability reduces commercialization risk

EQ-001 is licensed from Biocon, which manufactures the antibody at an FDA-regulated commercial-scale facility. The availability of established manufacturing infrastructure reduces one of the major risks commonly associated with late-stage biologic development and could facilitate rapid commercial supply if regulatory approval is obtained. Additionally, both intravenous and subcutaneous formulations have been developed, providing flexibility for future clinical and commercial use.

EQ-001 Recent Developments

In October 2024, Equillium Inc. announced that Ono Pharmaceutical Co., Ltd. (Ono) has made the strategic business decision to allow its option to acquire Equillium’s rights to Itolizumab to expire. The decision was not related to data from any clinical program and there have been no observed or reported safety concerns. As a result, Equillium maintains all of its commercial rights to Itolizumab.

“EQ-001 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of EQ-001 for approved indication like Plaque psoriasis, Cytokine release syndrome, SARS-CoV-2 acute respiratory disease; as well as potential indication like GvHD, Ulcerative colitis, Lupus nephritis, Systemic lupus erythematosus in the 7MM. A detailed picture of EQ-001’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the EQ-001 for approved and potential indications. The EQ-001 market report provides insights about EQ-001’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current EQ-001 performance, future market assessments inclusive of the EQ-001 market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of EQ-001 sales forecasts, along with factors driving its market.

EQ-001 Drug Summary

EQ-001 (Itolizumab) is a humanized IgG1 monoclonal antibody being developed by Equillium as an immunomodulatory therapy for T-cell-mediated autoimmune and inflammatory diseases. The antibody targets CD6, a co-stimulatory receptor expressed on effector T cells, where it modulates T-cell activation, proliferation, trafficking, and cytokine production without causing broad T-cell depletion. By selectively dampening pathogenic immune responses while preserving much of normal immune function, EQ-001 has been investigated across multiple indications, including acute graft-versus-host disease (aGVHD), lupus nephritis, ulcerative colitis, and asthma, although development priorities have evolved over time. Administered as an intravenous infusion, EQ-001 has demonstrated immunomodulatory activity and an acceptable safety profile in early- and mid-stage clinical studies, supporting its potential as a targeted therapy for diseases driven by aberrant T-cell activation. Its differentiated mechanism of action and potential to reduce inflammatory tissue damage while minimizing generalized immunosuppression position EQ-001 as a promising investigational biologic in immune-mediated disorders. The report provides EQ-001’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the EQ-001 Market Report

The report provides insights into:

• A comprehensive product overview including the EQ-001 MoA, description, dosage and administration, research and development activities in approved indications like Plaque psoriasis, Cytokine release syndrome, SARS-CoV-2 acute respiratory disease; as well as potential indication like GvHD, Ulcerative colitis, Lupus nephritis, Systemic lupus erythematosus.
• Elaborated details on EQ-001 regulatory milestones and other development activities have been provided in EQ-001 market report.
• The report also highlights EQ-001‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The EQ-001 market report also covers the patents information, generic entry and impact on cost cut.
• The EQ-001 market report contains current and forecasted EQ-001 sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The EQ-001 market report also features the SWOT analysis with analyst views for EQ-001 in approved and potential indications.

Methodology

The EQ-001 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

EQ-001 Analytical Perspective by DelveInsight

• In-depth EQ-001 Market Assessment

This EQ-001 sales market forecast report provides a detailed market assessment of EQ-001 for approved indication like Plaque psoriasis, Cytokine release syndrome, SARS-CoV-2 acute respiratory disease; as well as potential indication like GvHD, Ulcerative colitis, Lupus nephritis, Systemic lupus erythematosus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted EQ-001 sales data uptil 2034.

• EQ-001 Clinical Assessment

The EQ-001 market report provides the clinical trials information of EQ-001 for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

EQ-001 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

EQ-001 Market Potential & Revenue Forecast

• Projected market size for the EQ-001 and its key indications
• Estimated EQ-001 sales potential (EQ-001 peak sales forecasts)
• EQ-001 Pricing strategies and reimbursement landscape

EQ-001 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• EQ-001 Market positioning compared to existing treatments
• EQ-001 Strengths & weaknesses relative to competitors

EQ-001 Regulatory & Commercial Milestones

• EQ-001 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

EQ-001 Clinical Differentiation

• EQ-001 Efficacy & safety advantages over existing drugs
• EQ-001 Unique selling points

EQ-001 Market Report Highlights

• In the coming years, the EQ-001 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The EQ-001 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence EQ-001’s dominance.
• Other emerging products for Plaque psoriasis, Cytokine release syndrome, SARS-CoV-2 acute respiratory disease; as well as potential indication like GvHD, Ulcerative colitis, Lupus nephritis, Systemic lupus erythematosus are expected to give tough market competition to EQ-001 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of EQ-001 in approved and potential indications.
• Analyse EQ-001 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted EQ-001 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of EQ-001 in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of EQ-001? How strong is EQ-001’s clinical and commercial performance?
• What is EQ-001’s clinical trial status in each individual indications such as Plaque psoriasis, Cytokine release syndrome, SARS-CoV-2 acute respiratory disease; as well as potential indication like GvHD, Ulcerative colitis, Lupus nephritis, Systemic lupus erythematosus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EQ-001 Manufacturers?
• What are the key designations that have been granted to EQ-001 for approved and potential indications? How are they going to impact EQ-001’s penetration in various geographies?
• What is the current and forecasted EQ-001 market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of EQ-001 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to EQ-001 for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is EQ-001? What is the duration of therapy and what are the geographical variations in cost per patient?